Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.

Of specific relevance for human AML, in leukemia driven by both NPM1c and a FLT3 activating mutation a highly significant survival advantage was demonstrated ( P =0.008)( Figure 6d ).

also in 132,142 other papers